Chemical Hygiene Plan and Safety Manual - LP3050.3

Bloodborne Pathogen Exposure Control Plan

1.0 Purpose

The purpose of this Exposure Control Plan (ECP) is to establish and maintain bloodborne pathogen safety standards for Purity Laboratories, Inc (Purity) These standards will help to eliminate or minimize occupational exposure to bloodborne pathogens in accordance with OSHA standard 29 CFR 1910 1030 This procedure outlines the determination of employee exposure, methods of compliance, personal protective equipment, engineering and work practice controls This procedure details the proper way biological hazards are handled and exposure to pathogens is minimized and prevented This policy helps to ensure that all laboratory operations are conducted using safe working practices and that all applicable local, state and federal regulations and policies are being correctly implemented. Employees that will have occupational exposure to blood and or other potentially infectious materials (OPIM) are required to be trained in bloodborne pathogen handling and exposure as outlined in this procedure. This training will include all handling, testing and verification of blood, OPIM or blood materials and will include the universal precautions for potential exposure.

2.0 Scope

This procedure applies to all clinical personnel employed at Purity Laboratories, Inc. and to anyone otherwise working on clinical processes on the premises.

3.0

Safety

Normal chemistry laboratory precautions apply, including eye protection, lab coat and other protective precautions as required.

4.0 Definitions

4 1 BSL: Biosafety level The level of the biocontainment precautions required to isolate dangerous biological agents in an enclosed facility The levels of containment range from 1-4 depending on the danger of the hazard with 4 being the most hazardous

4 2 Bloodborne Pathogens: pathogenic microorganisms that are present in human blood and can cause disease in humans These pathogens include, but are not limited to, hepatitis B virus (HBV) and human immunodeficiency virus (HIV)

4.3 CLIA: Clinical Laboratory Improvement Amendments. Regulatory quality standards for all laboratory testing to ensure the accuracy, reliability and timeliness of patient test results regardless of where the test was performed.

4.4 Clinical Laboratory: a workplace where diagnostic or other screening procedures are performed on blood, specimens derived from humans or other potentially infectious materials.